| Literature DB >> 19856921 |
Nathalie Schlienger1, Birgitte W Lund, Jan Pawlas, Fabrizio Badalassi, Fabio Bertozzi, Rasmus Lewinsky, Alma Fejzic, Mikkel B Thygesen, Ali Tabatabaei, Stefania Risso Bradley, Luis R Gardell, Fabrice Piu, Roger Olsson.
Abstract
Herein we describe the discovery of ACP-105 (1), a novel and potent nonsteroidal selective androgen receptor modulator (SARM) with partial agonist activity relative to the natural androgen testosterone. Compound 1 was developed from a series of compounds found in a HTS screen using the receptor selection and amplification technology (R-SAT). In vivo, 1 improved anabolic parameters in a 2-week chronic study in castrated male rats. In addition to compound 1, a number of potent antiandrogens were discovered from the same series of compounds whereof one compound, 13, had antagonist activity at the AR T877A mutant involved in prostate cancer.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19856921 DOI: 10.1021/jm901149c
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446